Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. The company’s pipeline is led by two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease. Maze is based in South San Francisco.
Company Details
- Employees
- 146
- Founded
- -
- Address
- 171 Oyster Point Blvd,
- in****@****etx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- mazetx.com
- HQ
- South San Francisco, California
Maze Therapeutics Questions
Maze Therapeutics's website is mazetx.com
Maze Therapeutics's LinkedIn profile is https://www.linkedin.com/company/mazetx
Maze Therapeutics has
146 employees.
View email and phone details for 146
employees at Maze Therapeutics.
Maze Therapeutics's industry is
Biotechnology Research
Maze Therapeutics's top competitors are
Metsera,
Denali Therapeutics,
Allogene Therapeutics,
Bridgebio,
Eikon Therapeutics,
Pliant Therapeutics,
Arsenal Biosciences, Inc.,
Revolution Medicines,
Arcus Biosciences,
Nurix Therapeutics.
Maze Therapeutics's support email address is info@mazetx.com
Maze Therapeutics's categories are Biotechnology Research
Maze Therapeutics's founding year is 2018
